Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy i ...

The New Drug Application (NDA) for niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT), plus prednisone, has been submitted to the Food and Drug ...

Two years of abiraterone acetate plus prednisolone-based therapy significantly improved survival among men with high-risk nonmetastatic prostate cancer starting androgen deprivation therapy ...

Background: Abiraterone acetate (a prodrug of abiraterone, which is a selective inhibitor of androgen biosynthesis) combined with prednisone/prednisolone (AA+P) and enzalutamide (ENZ) (an ...

New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant ...

The addition of abiraterone acetate to prednisone significantly improved survival and delayed disease progression among men with metastatic castration-resistant prostate cancer who had not ...

Changes in prostate-specific antigen (PSA) levels with abiraterone acetate plus prednisone. Waterfall plots of (A) maximum PSA change and (B) change at week 12. Patients with prior ketoconazole ...

Chi KN, Rathkopf DE, Smith MR, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with ...

“With an additional 10.6 months of follow-up, (Keytruda) plus abiraterone acetate and prednisone continued to show antitumor activity and acceptable safety in patients with chemotherapy-naive ...

Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest population of BRCA-posit ...

Akeega is the first dual-action tablet consisting of a PARP inhibitor and abiraterone acetate, according to a press release from Janssen, the manufacturer of the drug. The FDA approval was based on ...